Related Experiment Video
Updated: Nov 1, 2025
07:17
Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
Published on: May 9, 2018
8.2K
Changing Paradigms: Green Laser Vaporization for Prostates over 80 mL: A Comparative Study
Carlos Gustavo Trujillo1, Laura Zuluaga1, Mauricio Plata1
1Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Bogotá, Colombia.
Journal of Endourology
|June 25, 2021
Summary
GreenLight Photovaporization of the Prostate (PVP) is effective for benign prostatic enlargement, even in larger prostates over 80mL. This laser therapy offers similar efficacy and short recovery times compared to smaller prostates, establishing it as a viable treatment option.
Area of Science:
- Urology
- Minimally Invasive Surgery
- Laser Therapeutics
Background:
- Benign prostatic enlargement (BPE) is a common condition affecting a significant portion of the aging male population.
- Photovaporization of the Prostate (PVP) using the GreenLight™ laser is an established treatment for BPE, particularly for prostates <80mL.
- The efficacy and safety of PVP for larger prostates (≥80mL) require further evaluation as an alternative to traditional surgical interventions.
Purpose of the Study:
- To evaluate the efficacy, safety, and functional outcomes of GreenLight laser PVP in patients with benign prostatic enlargement.
- To compare outcomes between patients with prostate volumes less than 80mL and those with volumes greater than or equal to 80mL.
- To assess PVP as a potential first-line treatment alternative for larger prostates.
Main Methods:
- A retrospective analysis of 840 patients who underwent GreenLight laser PVP between 2012 and 2019.
- Patients were stratified into two groups based on prostate volume: Group 1 (<80mL) and Group 2 (≥80mL).
- Primary outcomes included changes in prostate-specific antigen (PSA), International Prostatic Symptom Score (IPSS), quality of life, and safety parameters (Clavien-Dindo classification).
Main Results:
- While larger prostates (Group 2) required longer operative times and higher energy use, efficacy outcomes (IPSS reduction, PSA drop) were comparable between groups.
- Group 2 demonstrated a higher rate of conversion to other procedures and blood transfusions, highlighting the importance of surgeon experience.
- No significant differences were observed in hospital stay, catheterization duration, urethral stricture rates, or re-treatment rates between the groups.
Conclusions:
- GreenLight PVP is a safe and effective treatment for benign prostatic enlargement in prostates ≥80mL, offering similar benefits to smaller prostates.
- Key advantages include short hospital stays and catheterization times, making it a favorable option for patients with larger prostates.
- Surgeon experience is crucial for minimizing complications such as conversion and transfusion, supporting PVP as a first-line alternative for larger prostates.
